An open‐label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency
Authors:
- V Ram PeddiVPV Ram Peddi
- Stephen JensikSJStephen Jensik
- Mark PescovitzMPMark Pescovitz
- John PirschJPJohn Pirsch
- Scott H AdlerSAScott H Adler
- J Richard ThistlethwaiteJTJ Richard Thistlethwaite
- Flavio VincentiFVFlavio Vincenti
- David J CohenDCDavid J Cohen
- 16 December 2004
- journal article
- clinical trial
- Published by Wiley in Clinical Transplantation
- Vol. 19 (1) , 130-136
Abstract
Abstract: This pilot study was designed to evaluate the safety and efficacy of converting from a calcineurin inhibitor (CI) to a sirolimus (SRL)‐based regimen in established renal transplant recipients with moderate renal insufficiency. Sixty renal transplant recipients on CI‐based immuno‐suppression with a serum creatinine (SCr) between 159 and 265 μM (1.8 and 3.0 mg/dL) and a glomerular filtration rate (GFR) between 30 and 70 mL/min were enrolled. SRL dosing was dependent upon concomitant immunosuppressive therapy. The mean patient age was 45 yr and the mean time from transplant to study enrollment was 60.8 months (range: 7–198). The median SCr was 168 μM (1.9 mg/dL) and the median GFR was 51 mL/min. Twelve months after conversion the patient and graft survival rates were 96.7% and 95%, respectively. The incidence of biopsy‐proven acute rejection was 3.3% (two cases reported, Banff grades IA and IB). The median SCr and median creatinine clearance were 168 μM (1.9 mg/dL) and 53 mL/min, respectively. Hyperlipidemia, diarrhea, peripheral edema, rash, and anemia were the most commonly reported adverse events. Patients with moderate renal insufficiency can be converted from CI to SRL‐based therapy and maintain renal function over a 1‐yr period.Keywords
This publication has 24 references indexed in Scilit:
- Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study1 2Transplantation, 2003
- Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1Transplantation, 2003
- Sirolimus Does Not Exhibit Nephrotoxicity Compared to Cyclosporine in Renal Transplant RecipientsAmerican Journal of Transplantation, 2002
- SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10Transplantation, 2001
- SIROLIMUS IN ASSOCIATION WITH MYCOPHENOLATE MOFETIL INDUCTION FOR THE PREVENTION OF ACUTE GRAFT REJECTION IN RENAL ALLOGRAFT RECIPIENTS12Transplantation, 2000
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- HISTOPATHOLOGIC FINDINGS FROM 2-YEAR PROTOCOL BIOPSIES FROM A U.S. MULTICENTER KIDNEY TRANSPLANT TRIAL COMPARING TACROLIMUS VERSUS CYCLOSPORINETransplantation, 1998
- PREDICTING GLOMERULAR FILTRATION RATE AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995
- THE EFFECT OF RAPAMYCIN ON KIDNEY FUNCTION IN THE SPRAGUE-DAWLEY RATTransplantation, 1992